1 himself, 2 of the small studies he referred to that did not show a clear-cut BP response to RDN included ≤10 patients from single centers. Those results have to be weighed against a total of 259 patients included in the SYMPLICITY HTN-1 and HTN-2 studies, with follow-up as long as 3 years. Calculating responder rates and expressing them as a percentage in patient groups of <10 seems questionable to say the least. The recent report by Persu et al 3 was not published at the time of submission of our article. This study, labeled a subject-level meta-analysis, included 109 patients with resistant hypertension recruited from 10 European centers that each applied different recruitment criteria and included data from patients treated with various RDN devices. Nevertheless, the reported response rate, defined as systolic BP reduction ≥10 mm Hg, was 72% in patients with baseline office systolic BP ≥160 mm Hg. Although this response rate is lower than the 84% reported in similar patients in SYMPLICITY HTN-2, it is still remarkable.Although the Witkowski study did not report a significant reduction in ambulatory BP despite a reduction in office BP after RDN, that study only included 10 patients.